News OSE-immunotherapeutics Home > OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer > OSE-immunotherapeutics 18 July 2017
